Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1872-1880

  Shah, Dimpy P ^a,b   Ghantoji, Shashank S ^a,b   Shah, Jharna N ^c   El Taoum, Katia K ^a   Jiang, Ying ^a   Popat, Uday ^a   Hosing, Chitra ^a   Rondon, Gabriela ^a   Tarrand, Jeffrey J ^a   Champlin, Richard E ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Immunocompromised; Pneumonia; Rsv; Stem cell transplantation

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

ADOLESCENT; ADULT; AEROSOL; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FACE MASK; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PNEUMONIA; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VULNERABLE POPULATION;

IMMUNOCOMPROMISED; PNEUMONIA; RSV; STEM CELL TRANSPLANTATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TEXAS; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880752018     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt111     Document Type: Article

References (27)

1. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-63.
2. Whimbey E, Champlin RE, Couch RB et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22: 778-82.
3. Khanna N, Widmer AF, Decker M et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46: 402-12.
4. Raboni SM, Nogueira MB, Tsuchiya LRV et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76: 142-6.
5. Martino R, Porras RP, Rabella N et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 781-96.
6. Schiffer JT, Kirby K, Sandmaier B et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94: 1101-8.
7. Englund JA, Sullivan CJ, Jordan MC et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109: 203-8.
8. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001; 7 Suppl: 5S-7S.
9. Boeckh M, Berrey MM, Bowden RA et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350-4.
10. Boeckh M, Englund J, Li Y et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245-9.
11. Chemaly RF, Ghosh S, Bodey GP et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85: 278-87.
12. Avetisyan G, Mattsson J, Sparrelid E et al. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation 2009; 88: 1222-6.
13. McCarthy AJ, Kingman HM, Kelly C et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24: 1315-22.
14. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987-93.
15. Lewinsohn DM, Bowden RA, Mattson D et al. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996; 40: 2555-7.
16. Machado CM, Boas LS, Mendes AV et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31: 695-700.
17. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl: 11S-5S.
18. Ghosh S, Champlin RE, Englund J et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25: 751-5.
19. de Fontbrune FS, Robin M, Porcher R et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45: 1019-24.
20. Torres HA, Aguilera EA, Mattiuzzi GN et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica 2007; 92: 1216-23.
21. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125-37.
22. Boeckh MJ, Gooley T, Englund J et al. Respiratory syncytial virus (RSV) infection in hematopoietic stem cell transplant (HCT) recipients: risk factors for acquisition and lower respiratory tract disease, and impact on mortality. ASH Annual Meeting Abstracts 2004; 104: 187.
23. Sparrelid E, Ljungman P, Ekelof-Andstrom E et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905-8.
24. Schleuning M, Buxbaum-Conradi H, Jager G et al. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J 2004; 5: 135-44.
25. Hall CB, McBride JT, Walsh EE et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308: 1443-7.
26. Hertz MI, Englund JA, Snover D et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 1989; 68: 269-81.
27. Granwehr BP, Chemaly RF, Kontoyiannis DP. Fungal and viral infections in cancer patients. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson Manual of Medical Oncology. Houston, TX: The McGraw-Hill Companies, 2011; 1205-34.